Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07665879
PHASE1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.

Official title: A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

115

Start Date

2026-06

Completion Date

2027-08

Last Updated

2026-06-24

Healthy Volunteers

Yes

Interventions

DRUG

Eloralintide

Eloralintide administered SC

OTHER

Placebo

Placebo administered SC

Locations (1)

Profil Institut für Stoffwechselforschung

Neuss, Germany